Through our Organizational Regulations, the Board of Directors has delegated the responsibility and authority necessary or appropriate for carrying out the day-to-day and operational activities of PolyPeptide to the Executive Committee under the leadership of the CEO.

The CEO is accountable for the sustainable management and results-oriented performance of the Group. As such, the CEO leads, manages, supervises and coordinates the Executive Committee and the PolyPeptide Management Committee as well as executes the corporate goals and strategy as set by the Board of Directors. The detailed responsibilities and functions of the Executive Committee, including the CEO and the CFO, are described in section 6 of the Organizational Regulations.

In general, meetings of the Executive Committee take place as determined by the CEO, with the expectation that there be no fewer than six such meetings per calendar year (as provided for in the Organizational Regulations). For the year ended 31 December 2024, the Executive Committee met six (6) times, in a combination of in-person sessions and video conferences, for an average duration of approximately one and a half (1.5) hours. The resolutions of the Executive Committee are taken by the majority of the members of the Executive Committee present, where the CEO has the power to overrule any Executive Committee resolution. At each meeting, the CFO presents the financial situation of the Group, followed by a discussion on other non-financial predetermined agenda items covering a range of topics across all relevant business and operational areas. The Organizational Regulations set forth procedures to address conflicts of interest.

4.1 Members of the Executive Committee

As of 31 December 2024, the Executive Committee comprised the CEO, the CFO, the General Counsel and the Director Global Operations. Neil James Thompson stepped down as Director Global Sales and Marketing as of 26 April 2024.¹⁴ The Board of Directors subsequently decided to reduce the size of the Executive Committee to concentrate focus on strategic operational and financial matters. The year of appointment in the table below reflects each Executive Committee member’s respective appointment in their current position with the Group (including at Group subsidiaries).

Set out below is a short description of the business experience, education and activities for each Executive Committee member in office as of 31 December 2024.

Juan José González

Chief Executive Officer

Nationality: Peruvian and American

Year of birth: 1972

Professional background

Functions at PolyPeptide

• Chief Executive Officer (since 2023)
• Chair / Member of the board of directors of several PolyPeptide subsidiaries (since 2023)

Outside mandates at listed / non-listed companies or non-profit organizations

• None

Former outside activities and functions

• Member of the board of directors and Member of the Audit & Remuneration Committee, Straumann Group, Switzerland (2019–April 2024)
• Chief Executive Officer, Ambu, Denmark (2019–2022)
• Various senior roles within the Johnson & Johnson Group, US (2007–2019), including Global Vice President, Smoking Cessation, OTC division, UK, (2007), Area Managing Director, Consumer sector, United Kingdom (2011–2013) and ultimately serving as President Orthopeadics, Medical Devices sector, US (2016–2019)
• Commercial Director Europe, Middle East and Africa, Pfizer Inc. Consumer Healthcare Division, UK, (2004–2006)
• Engagement Manager, U.S., Europe, Asia Pacific and Latin America–Global Consumer and Private Equity Practices, McKinsey & Company, US (1999–2004)
• Country Marketing and Sales manager–Consumer Electronics and Home Application Retail Division, Repsol, Peru (1996–1997)
• Sales Supervisor, Peru (1993–1994) and Regional Sales Manager, Peru, Ecuador and Bolivia (1995), The Procter & Gamble Company, Peru (1993–1995)

Education

• Master of Technology Management, Columbia University, New York, US (2016)
• MBA in Marketing and Corporate Finance, University of Notre Dame, US (1999)
• Bachelor of Science in Industrial Engineering, University of Lima, Peru (1993)

Read More

Marc Augustin

Chief Financial Officer

Nationality: German

Year of birth: 1972

Professional background

Functions at PolyPeptide

• Chief Financial Officer (since 2024)

Outside mandates at listed / non-listed companies or non-profit organizations

• None

Former outside activities and functions

• Head Finance Mammalian and Microbial Business Unit, Vice President Finance Biologics and Global Head Sales Excellence Biologics, Lonza AG, Switzerland (2016–2023)
• Finance Director Switzerland, Head of Finances Operations Orthopaedics Europe, Smith & Nephew Orthopaedics AG, Switzerland (2009–2016)
• Head Of Finance & Administration (Site Controller), Alcoa Extrusion Hannover GmbH & CO. KG, Germany (2008–2009)
• Business Unit Controller Accessibility, ThyssenKrupp Elevator AG, Germany (2004–2008)
• Senior Project Manager M&A / Controlling, ThyssenKrupp Services AG, Germany (2001–2004)
• Management Trainee, Babcock Borsig AG, Germany (1998–2001)

Education

• MBA in Controlling, Tax, Heinrich-Heine-Universität Düsseldorf, Germany (1998)

Read More

Christina Del Vecchio

General Counsel

Nationality: Swiss and Swedish

Year of birth: 1978

Professional background

Functions at PolyPeptide

• Chief Legal Officer and Corporate Secretary (since 2025)
• General Counsel and Corporate Secretary (2021–2024)
• Member of the board of directors of a PolyPeptide subsidiary (since 2023)

Outside mandates at listed / non-listed companies or non-profit organizations

• None

Former outside activities and functions

• Counsel, Niederer Kraft Frey AG, Switzerland (2018–2021)
• Senior Associate, Niederer Kraft Frey AG, Switzerland (2013–2018)
• Associate, Latham & Watkins LLP, United Kingdom (2008–2012)

Education

• Juris Doctor, James Kent Scholar, Columbia Law School, US (2008)
• Bachelor of Arts, summa cum laude, University of Florida, US (2000)

Read More

Jens Fricke

Director Global Operations

Nationality: Danish

Year of birth: 1965

Professional background

Functions at PolyPeptide

• Director Global Operations (since 2022)
• Member of the board of directors of several PolyPeptide subsidiaries (since 2021)
• General Director Scandinavia (2013–2022)

Outside mandates at listed / non-listed companies or non-profit organizations

• None

Former outside activities and functions

• Director API Production, LEO Pharma, Denmark (2008–2013)
• Leading positions with increasing responsibilities in Aseptic Production and API Production, ALK Abello, Denmark (1998–2008)
• Chemist at Novo Nordisk / Hema Sure, Denmark (1995–1998)

Education

• Master of Sciences in Biochemistry, the University of Copenhagen, Denmark (1993)
• Strategic Leadership, IMD Lausanne, Switzerland (2011)

Read More

In 2024, the Executive Committee, under the leadership of the CEO, was further supported by additional members of management, that, together with the Executive Committee, formed the PolyPeptide Management Committee.

4.2 Other activities and vested interests

Except as disclosed in the biographies of the members of the Executive Committee, no further activities or vested interests are carried out outside of PolyPeptide.

4.3 Mandates and other permitted activities

In accordance with Swiss law, our Articles of Association limit the number of functions in superior management or administrative bodies of legal units other than with PolyPeptide that members of the Executive Committee are allowed to hold at one time.

Pursuant to art. 23 of the Articles of Association, with the approval of the Board of Directors, the members of the Executive Committee may have the following comparable functions at other companies with an economic purpose (including their group):

• up to one (1) mandate as member of the board of directors or any other superior management or administrative body of listed companies; and, in addition
• up to five (5) mandates as member of the board of directors or any other superior management or administrative body of other legal entities that do not meet the above mentioned criteria.

With respect to the additional activities of the members of the Executive Committee, mandates in companies that are under uniform control or the same beneficial ownership are deemed to be one mandate.

The following mandates shall not be subject to the limitations set forth in art. 23 of the Articles of Association:

• mandates in companies which are controlled by the Company or which control the Company;
• mandates held at the request of the Company or companies controlled by it; no member of the Executive Committee shall, however, hold more than ten (10) such mandates; and
• mandates in associations, charitable organizations, foundations, employee welfare foundations and other similar organizations; no member of the Executive Committee shall, however, hold more than fifteen (15) such mandates.

4.4 Management contracts

The Company and its subsidiaries have not entered into any management contracts with third parties.

4.5 Gender guidelines

As of 31 December 2024, one (1) out of four (4) members of the Executive Committee was female (25%). The Remuneration and Nomination Committee, together with the Board of Directors, actively considers gender diversity in succession planning of the Executive Committee.